# Tolerance of Intraperitoneal (IP) Nivolumab After Extensive Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Ovarian Carcinoma

> **NCT03959761** · PHASE1,PHASE2 · COMPLETED · sponsor: **Hospices Civils de Lyon** · enrollment: 22 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Intraperitoneal (IP) nivolumab infusion

## Key facts

- **NCT ID:** NCT03959761
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-17
- **Primary completion:** 2022-10-03
- **Final completion:** 2022-10-03
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03959761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03959761, "Tolerance of Intraperitoneal (IP) Nivolumab After Extensive Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Ovarian Carcinoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03959761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*